1
0
0
News
새로운 HER3 표적 암 치료 항체 - BRIC
www.ibric.org
독일 로쉬 진단 연구소(Roche Diagnostics GmbH) 의 버지트 보센마이어 (Birgit Bossenmaier) 박사 연구팀은 HER3 활성화를 차단하고 HER3 발현을 감소시키며 Fc의 ... › read
Netzwerk-Profile
LinkedIn: Birgit Bossenmaier | LinkedIn
Birgit Bossenmaiers berufliches Profil anzeigen LinkedIn ist das weltweit größte berufliche Netzwerk, ... Focus Area Head & Senior Principal Scientist at Roche.
LinkedIn: Birgit Bossenmaier | LinkedIn
Sehen Sie sich das berufliche Profil von Birgit Bossenmaier (Deutschland) auf LinkedIn an. LinkedIn ist das weltweit größte professionelle Netzwerk, das Fach Es fehlt: hildesheim
Interessen
Birgit Bossenmaier - Patents
www.freshpatents.com
Birgit Bossenmaier - bibliographic patent references ... If Birgit Bossenmaier filed recent patent applications under another name, ...
Management & Beteiligungen
Birgit Bossenmaier in der Creditreform Firmendatenbank
www.firmenwissen.de
Birgit Bossenmaier steht mit folgenden Firmen in Beziehung. Es gibt derzeit 1 Unternehmen in der Firmendatenbank, mit denen Birgit Bossenmaier in Beziehung steht. Bei der Art der Beziehung kann es sich beispielsweise um eine Position als Manager, Geschäftsführer oder Gesellschafter handeln.
Business-Profile
patentbuddy: Birgit Bossenmaier
HOFFMANN-LA ROCHE INC.
Besitz
US HER3/HER2 bispecific antibodies binding to the...
patentscope.wipo.int
This patent search tool allows you not only to search the PCT database of about 2 million International Applications but also the worldwide patent collections....
Bücher
LymphedemaV1, Pmc, Corpus, indexItem, Author.i, Birgit Bossenmaier
lorexplor.istex.fr
› Site › in...
PLOS ONE: Direct estrogen receptor (ER) / HER family crosstalk...
journals.plos.org
Birgit Bossenmaier. Affiliation Roche Innovation Center Munich, Penzberg, Germany. ORCID logo http://orcid.org
AACR Proceedings: Abstracts American Association for...
books.google.de
The AACR Annual Meeting highlights the best cancer science and medicine from institutions all over the world. Attendees are invited to stretch their...
List of Members - European Association for the Study of Diabetes -...
books.google.de
... Dr Birgit Bossenmaier Fa, Boehringer Mannheim GmbH Department TF-MM D Mannheim Germany Tel + Fax + ...
Dokumente zum Namen
31st Annual Meeting and Associated Programs of the Society for ...
www.scienceopen.com
... Tapan Bera, Masaki Terabe, Birgit Bossenmaier, Gerhard Niederfellner, Yoram Reiter, Ira Pastan, Leiming Xia, Yang Xia, Yangyang Hu, Yi Wang, Yangyi Bao, ...
MSACL-Ducret
www.msacl.org
Authorship: Axel Ducret(1), Ian James(2), Martina Feilke(3), Sabine Bader(3), Thomas Friess(2), Birgit Bossenmaier (2), Marlene Thomas (2), Maurizio Ceppi(2)
Combining anti-CTLA4 with RG7787, an immunotoxin targeting...
www.scienceopen.com
Authors: Jasmin Leshem, Xiu-fen Liu, Tapan Bera, Masaki Terabe, Jay A Berzofsky, Birgit Bossenmaier, Gerhard Niederfellner, Ira Pastan. Publication date ...
OASIS
www.abstractsonline.com
... Alexander Lifke, Adam Nopora, Frieder Bauss, Gerhard Niederfellner, Birgit Bossenmaier. Roche Diagnostics GmbH, Penzberg, Germany.
Wissenschaftliche Veröffentlichungen
FEBS Letters | Vol 449, Issues 2–3, Pages (23 April 1999) |...
www.sciencedirect.com
Volker Strack, Birgit Bossenmaier, Borislav Stoyanov, Luitgard Mosthaf, ... Hans-U. Häring. Pages : Download PDF. Article preview. › issue
Department of Medical Statistics, University Goettingenams.med.uni-goettingen.de › p-mgmt
ams.med.uni-goettingen.de
Max Hasmann and Birgit Bossenmaier (Roche Diagnostics GmbH) Tim Beissbarth, Annalen Bleckmann, Tobias Pukrop and Christine Stadelmann-Nessler
Veröffentlichungen allgemein
EconPapers: Deciphering the Stepwise Binding Mode of HRG1β to HER3 by...
econpapers.repec.org
By Carmen Peess, Leopold von Proff, Sabine Goller, Karl Andersson, Michael Gerg, Magnus Malmqvist, Birgit Bossenmaier and Michael Schräml; Abstract: For ...
Cancer Chemotherapy and Pharmacology | Volume 75, issue 4
link.springer.com
Georgina Meneses-Lorente; Thomas Friess; Birgit Bossenmaier. Content type: Original Article; Open Access; Published: 22 February 2015; Pages: › journal
Oalib search
www.oalib.com
Abstract: Cub domain containing protein 1 (CDCP1) is strongly expressed in tumors derived from lung, colon, ovary, or kidney. It is a membrane protein that is ...
Sonstiges
US B2 - Oxidized thioether derivatives - Google Patents
patents.google.com
Application number: US ,065; Other versions: US A1 (en; Inventor: Birgit Bossenmaier: Walter-Gunar Friebe: Thomas Friess: Lothar Kling ... › patents
Volume 21, Issue 3, Pages (March 2014) - ppt download
slideplayer.com
... Birgit Bossenmaier, Marlene Thomas, Christian Klein, Alfred Mertens, Astrid Heller, Michael Tacke Chemistry & Biology Volume 21, Issue 3, Pages (March ... › slide
Birgit Bossenmaier, Seefeld DE - Patent applications
www.patentsencyclopedia.com
Patent application number, Description, Published , Bispecific Anti ErbB2 / Anti cMet Antibodies - The present invention relates to bispecific ...
Altmetric – Acquired Resistance to Antibody-Drug Conjugates
mdpi.altmetric.com
Published in. Cancers, March DOI, cancers Pubmed ID Authors. Denis Collins, Birgit Bossenmaier, Gwendlyn Kollmorgen, ...
Acquired Resistance to Antibody-Drug Conjugates - MDPI
www.mdpi.com
von DM Collins · · Zitiert von: 62 — Birgit Bossenmaier. 2 ,. Gwendlyn Kollmorgen. 3 and. Gerhard Niederfellner. 4,*. 1. National Institute for Cellular Biotechnology, Dublin City University, ... › ...
Birgit - Patent applications
www.patentsencyclopedia.com
Birgit Bossenmaier, Seefeld DE. Patent application number, Description, Published ... Patent applications by Birgit Bossenmaier, Seefeld DE. › ...
Cancers | Free Full-Text | Acquired Resistance to Antibody-Drug...
www.mdpi.com
by Denis M. Collins 1, Birgit Bossenmaier 2 , Gwendlyn Kollmorgen 3 and Gerhard Niederfellner 4,*. 1. National Institute for Cellular Biotechnology, Dublin City ...
Lumretuzumab and pertuzumab both potently inhibit HER2/HER3 signaling.
plos.figshare.com
Lumretuzumab and pertuzumab both potently inhibit HER2/HER3 signaling.
Bispecific antibody derivatives with restricted binding ...
academic.oup.com
von S Metz · · Zitiert von: 43 — Birgit Bossenmaier,. Birgit Bossenmaier. 2. Roche Pharma Research & Early Development (pRED), Discovery Oncology. ,. Nonnenwald 2, D Penzberg. › peds
Bispecific antibody derivatives with restricted binding...
read.qxmd.com
... Croasdale, Eike Hoffmann, Britta Schneider, Johannes Auer, Christian Gassner, Birgit Bossenmaier, Pablo Umana, Claudio Sustmann, Ulrich Brinkmann.
Combining anti-CTLA4 with RG7787, an immunotoxin targeting...
www.infona.pl
Jasmin Leshem, Xiu-fen Liu, Tapan Bera, Masaki Terabe, Jay A Berzofsky, Birgit Bossenmaier, Gerhard Niederfellner, Ira Pastan · Details · Contributors · Fields ...
Clinical trials (cancer treatment) | PLOS ONE
journals.plos.org
... Wei-Li Liao, Yuan Tian, Thomas Friess, Birgit Bossenmaier, Gabriele Dietmann, Christoph Schaab, Todd Hembrough, Maurizio Ceppi.
Create a SciFeed alert for new publications With following keywords ...www.mdpi.com › scifeed_display
www.mdpi.com
By following authors. Denis M. Collins. Birgit Bossenmaier. Gwendlyn Kollmorgen. Gerhard Niederfellner. With settings. Email: Freq: Daily, Weekly, Monthly ...
Immune Epitope Database (IEDB)www.iedb.org › assay
www.iedb.org
... Friess; Christian A Gerdes; Ulrike Reiff; Valeria Lifke; Gabriele Hoelzlwimmer; Irene Kolm; Karl-Peter Hopfner; Gerhard Niederfellner; Birgit Bossenmaier.
Direct estrogen receptor (ER) / HER family crosstalk mediating ...
journals.plos.org
... John Crown,; Andrés Cervantes, … Martin Weisser,; Birgit Bossenmaier. PLOS. x. Published: May 11, 2017; https://doi.org journal.pone › comments
ImmunoPET and biodistribution with human epidermal Pub Medpubmed.ncbi.nlm.nih.gov › ...
pubmed.ncbi.nlm.nih.gov
Anton G T Terwisscha van Scheltinga , Marjolijn N Lub-de Hooge , Keelara Abiraj , Carolien P Schröder , Linda Pot , Birgit Bossenmaier , Marlene Thomas ...
First-in-Human Phase I Study of Lumretuzumab, a Glycoengineered...
read.qxmd.com
... Marlene Thomas, Maurizio Ceppi, Georgina Meneses-Lorente, Ian James, Celine Adessi, Francesca Michielin, Keelara Abiraj, Birgit Bossenmaier, Jan H M ...
Development of Bispecific Molecules for the In Situ Detection of...
www.infona.pl
... Simon Stritt, Fabian Tetzlaff, Monika Soukupova, Erhard Kopetzki, Birgit Bossenmaier, Marlene Thomas, Christian Klein, Alfred Mertens, .
DuoMab: A Novel CrossMab-based IgG-derived Antibody ...pubmed.ncbi.nlm.nih.gov › ...
pubmed.ncbi.nlm.nih.gov
... Lothar Kling , Klaus-Peter Künkele , Manfred Schwaiger , Birgit Bossenmaier , Julia J Griese , Karl-Peter Hopfner , Alexandra Graff-Meyer , Henning Stahlberg ...
ImmunoPET and biodistribution with human epidermal growth factor...
docksci.com
P Schröder , Linda Pot , Birgit Bossenmaier , Marlene Thomas , Gabriele Hölzlwimmer , e b a. Thomas Friess , Jos GW Kosterink & Elisabeth ...
sortiert nach Relevanz / Datum